Evidence map›Paper›PMID 38634067›Full record

ArticleWellcome open research2023

Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies.

Spyridon Siafis, Robert McCutcheon, Virginia Chiocchia, Edoardo G Ostinelli, Simonne Wright, Claire Stansfield, Damian Omari Juma, Ioannis Mantas, Oliver D Howes, Grazia Rutigliano and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Wellcome open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 13 institutions in 8 countries.

Spyridon SiafisDepartment of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.ORCID https://orcid.org/0000-0001-8264-2039
Robert McCutcheonDepartment of Psychiatry, University of Oxford, Oxford, England, UK.
Virginia ChiocchiaInstitute of Social and Preventive Medicine, University of Bern, Bern, Canton of Bern, Switzerland.ORCID https://orcid.org/0000-0002-6196-3308
Edoardo G OstinelliDepartment of Psychiatry, University of Oxford, Oxford, England, UK.ORCID https://orcid.org/0000-0002-8717-0832
Simonne WrightDepartment of Psychiatry, Stellenbosch University, Stellenbosch, Western Cape, South Africa.ORCID https://orcid.org/0000-0003-3295-256X
Claire StansfieldEPPI Centre, Social Research Institute, University College London, London, England, UK.
Damian Omari JumaMy Mind Our Humanity, Mombasa, Kenya.
Ioannis MantasDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Oliver D HowesDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, UK.
Grazia RutiglianoInstitute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, England, UK.
Fiona RamageCentre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.
Francesca TinsdeallCentre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.ORCID https://orcid.org/0009-0008-9248-2954
Claire FriedrichDepartment of Psychiatry, University of Oxford, Oxford, England, UK.ORCID https://orcid.org/0000-0002-5841-4324
Lea MilliganMQ Mental Health Research, London, UK.ORCID https://orcid.org/0009-0003-7865-5533
Carmen MorenoDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense de Madrid, Madrid, Community of Madrid, Spain.
Julian H ElliottCochrane Australia, School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia.
James ThomasEPPI Centre, Social Research Institute, University College London, London, England, UK.ORCID https://orcid.org/0000-0003-4805-4190
Malcolm R MacleodCentre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.ORCID https://orcid.org/0000-0001-9187-9839
Emily S SenaCentre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.ORCID https://orcid.org/0000-0002-3282-8502
Soraya SeedatDepartment of Psychiatry, Stellenbosch University, Stellenbosch, Western Cape, South Africa.
Georgia SalantiInstitute of Social and Preventive Medicine, University of Bern, Bern, Canton of Bern, Switzerland.
Jennifer PottsDepartment of Psychiatry, University of Oxford, Oxford, England, UK.
Andrea CiprianiDepartment of Psychiatry, University of Oxford, Oxford, England, UK.
Stefan LeuchtDepartment of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
GALENOS team
University of Edinburgh · GBKing's College London · GBOxford Health NHS Foundation Trust · GBStellenbosch University · ZAUniversity College London · GBUniversity of Bern · CHUniversity of Oxford · GBUniversity of Thessaly · GRImperial College London · GBKarolinska Institutet · SEMental Health Research UK · GBMonash University · AUUniversidad Complutense de Madrid · ES

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundThere is an urgent need to develop more effective and safer antipsychotics beyond dopamine 2 receptor antagonists. An emerging and promising approach is TAAR1 agonism. Therefore, we will conduct a living systematic review and meta-analysis to synthesize and triangulate the evidence from preclinical animal experiments and clinical studies on the efficacy, safety, and underlying mechanism of action of TAAR1 agonism for psychosis.

methodsIndependent searches will be conducted in multiple electronic databases to identify clinical and animal experimental studies comparing TAAR1 agonists with licensed antipsychotics or other control conditions in individuals with psychosis or animal models for psychosis, respectively. The primary outcomes will be overall psychotic symptoms and their behavioural proxies in animals. Secondary outcomes will include side effects and neurobiological measures. Two independent reviewers will conduct study selection, data extraction using predefined forms, and risk of bias assessment using suitable tools based on the study design. Ontologies will be developed to facilitate study identification and data extraction. Data from clinical and animal studies will be synthesized separately using random-effects meta-analysis if appropriate, or synthesis without meta-analysis. Study characteristics will be investigated as potential sources of heterogeneity. Confidence in the evidence for each outcome and source of evidence will be evaluated, considering the summary of the association, potential concerns regarding internal and external validity, and reporting biases. When multiple sources of evidence are available for an outcome, an overall conclusion will be drawn in a triangulation meeting involving a multidisciplinary team of experts. We plan trimonthly updates of the review, and any modifications in the protocol will be documented. The review will be co-produced by multiple stakeholders aiming to produce impactful and relevant results and bridge the gap between preclinical and clinical research on psychosis. PROTOCOL REGISTRATION: PROSPERO-ID: CRD42023451628.

Indexed as

GALENOS; antipsychotic; neurotransmitters; pathophysiology; glutamate; schizophrenia; serotonin

Identifiers

PMID38634067
PMCPMC11021884
OpenAlexW4386167659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.